Precision Biologics Completes Patient Accrual to Its Ensituximab Phase 2 Colorectal Cancer Study



ROCKVILLE, Md.--(BUSINESS WIRE)--Precision Biologics is pleased to announce the completion of accrual to

its Phase 2 study utilizing its novel monoclonal antibody Ensituximab (NPC-1C).

NPC-1C targets a unique member of the MUC family that is specific to

colorectal cancer with little reactivity to normal cells. Encouraging

overall survival (OS) data was observed in the initial dose escalation

phase in patients with chemotherapy refractory metastatic colorectal

cancer. Patients in the preliminary study had an OS of 10.4 months,

comparing favorably to the historical control for a similar population

of patients (5.0 months). These results led to the current,

statistically powered Phase 2 design of the study in 47 patients with

colorectal cancer with a primary endpoint to increase overall survival

after treatment with NPC-1C. Results of the Phase 2 study will be

presented by Philip M. Arlen, MD, President and CEO of Precision

Biologics at the Oxford Global 16th Annual Drug Summit and 3rd

Annual Discovery Chemistry and Drug Designs Conference held on June 8th-9th,

2015 in Berlin, Germany. The presentation will be made available

following the conference on the Precision Biologics website, www.Precision-Biologics.com.

In addition, an abstract associated with this study is now available in

the ASCO Proceedings for the 2015 Annual Meeting: J Clin Oncol 33, 2015

(suppl; abstr e14013) http://abstracts.asco.org/156/AbstView_156_148099.html

Precision Biologics

Founded in February 2012 and commencing business in late September 2012,

Precision Biologics, Inc. is a clinical stage biotechnology corporation

focused on developing therapeutic and diagnostic products for the early

detection and treatment of cancer. Precision Biologics is uniquely

positioned to create innovative therapeutics through the use of

proprietary cancer vaccines, several of which have demonstrated success

in human trials.

Know more here.